What Tilam Treats: Main Uses and Benefits

Tilam (Imipenem/Cilastatin) is a specialized medication generally reserved for the most serious bacterial infections. It provides support in managing the pathogenic threat and easing associated critical symptomatic distress. This medicine is commonly used to help treat a wide array of serious infections that are caused by bacteria, including those in the respiratory tract, abdomen, blood, and joints.

Therapeutic Scope and Benefit

The medicine is commonly used to help with addressing life-threatening systemic infections such as sepsis and severe endocarditis, as well as complicated organ infections like hospital-acquired pneumonia and complex intra-abdominal infections. In these scenarios, the use of Tilam contributes to addressing the bacterial cause and is relevant in contexts involving acute symptoms that may disrupt systemic function.

The main benefit for the patient is the support provided in managing conditions characterized by periods of heightened symptoms. This action helps manage dangerously high fevers and assists with easing the burden of intense localized pain. The use of broad-spectrum agents is generally considered relevant for managing acute episodes where symptoms become temporarily overwhelming.

Quick Fact

Quick Fact: Relief for Systemic Imbalance Tilam may assist in maintaining functional stability and supports the patient during difficult episodes by easing the distress caused by resistant or widespread bacterial infections, which often manifest as high fever and inflammation.

Regulatory References

1. NIH MedlinePlus Drug Information on Imipenem and Cilastatin

Who Can and Cannot Use Tilam?

The eligibility for using Tilam (Imipenem/Cilastatin) is strictly defined by government regulatory documents, focusing on patient characteristics and pre-existing conditions.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with known severe hypersensitivity (e.g., anaphylaxis) to Imipenem, Cilastatin, or any other carbapenem or beta-lactam antibacterial agent [1.4, 2.1, 2.7].
Age-related eligibility rules	Adults and adolescents are generally approved for use. Use in children less than one year of age is not recommended due to insufficient clinical data [2.3]. Older adults may require dose adjustment if age-related renal function decline is present [2.3].
Condition-specific eligibility rules	Patients with severe renal impairment ( CL cr le 5 mL/min) must not receive the medicine unless haemodialysis is instituted within 48 hours [2.2, 2.6]. CNS disorders (e.g., history of seizures) require strict caution and continuation of anticonvulsant therapy [1.4, 2.2].
Physiological status restrictions	The medicine is not recommended for the treatment of meningitis [2.2]. Use during pregnancy is advised only if the benefit outweighs the risk to the foetus [2.1]. Use while lactating is generally not recommended by some authorities [2.1].

---

The official eligibility profile is structured around these absolute exclusions and conditional restrictions. Patients are prohibited from use based on a history of severe allergic reactions to the drug class. Use is restricted in populations with compromised renal function and those with CNS disorders due to increased risk of CNS adverse effects, as documented in prescribing information. The regulatory labeling outlines use in pediatric and reproductive populations based on established data or mandated risk-benefit assessments.

The official regulatory profile for Tilam (Imipenem/Cilastatin) is defined by specific pharmacokinetic, pharmacodynamic, and additive central nervous system (CNS) interactions. These documented patterns lead to formal restrictions on co-administration with several medicinal products and substances.

Interacting Substance	Official Regulatory Outcome
Valproic acid or Divalproex Sodium	Co-administration is generally not recommended as it reduces the serum concentration of valproic acid, which is officially documented to increase the potential for breakthrough seizures.
Ganciclovir	Co-administration is not recommended unless potential benefits outweigh the risks, based on reports of additive CNS effects and generalized seizures.
Probenecid	Co-administration results in an increase in the plasma level and half-life of Imipenem by officially documented inhibition of its renal tubular secretion, thereby decreasing its clearance.
Live Bacterial Vaccines	Tilam may decrease the intended effects of live bacterial vaccines, such as Cholera Vaccine Live, due to pharmacodynamic antagonism.

Population and Substance Notes

Patients with compromised renal function (creatinine clearances leq 30 mL/min) have an officially documented increased seizure potential because reduced drug clearance heightens the risk of CNS adverse reactions. Official labeling also notes that both the medicine and alcohol can contribute to confusion, defining an interaction risk through an additive CNS effect. The overall interaction structure is defined by restrictions against combinations that significantly modify drug exposure or those that increase the formally recognized risk of serious adverse events.

Cellular Disruption via Penicillin-Binding Protein Inhibition

The mechanism involves the direct, covalent inhibition of bacterial Penicillin-Binding Proteins (PBPs) by Imipenem. These enzymes are essential for constructing the final, rigid layer of the bacterial cell wall (peptidoglycan). By disabling the PBPs, the mechanism immediately halts cell wall synthesis, leading to the osmotic rupture and death (lysis) of the bacterial cell. This process results in the structural destruction of the bacterial cells and subsequent cessation of replication.

---

Enzymatic Protection and Pharmacodynamic Stabilization

The co-formulation includes Cilastatin, a specific inhibitor of the human enzyme Renal Dehydropeptidase-I (DHP-I). This enzyme normally metabolizes Imipenem in the kidneys. By blocking DHP-I, Cilastatin prevents the degradation of Imipenem, allowing the active, chemically intact molecule to remain stable, prolonging the duration of its bactericidal action against the targeted molecular pathways. This combination action ensures that the full molecular effect of Imipenem can be realized.

Tilam (Imipenem/Cilastatin) is administered exclusively through Intravenous (IV) Infusion, often requiring an inpatient or monitored setting, although specific formulations may allow for Intramuscular (IM) injection. The medicine is provided as a sterile powder for injection and must be reconstituted and diluted into a suitable IV solution prior to administration.

The dosing schedule is rigidly defined based on the Imipenem component. Standard adult doses range from 250 mg to 1000 mg per administration, with the maximum total daily dose not to exceed 4 grams (4000 mg). This total daily dose is divided and administered on a strict 6-hourly (q6h) or 8-hourly (q8h) schedule, a pattern classified as equally divided doses.

Procedural constraints govern the infusion. Administration requires careful control: doses less than or equal to 500 mg must be infused over 20 to 30 minutes, while larger doses up to 1000 mg require a 40 to 60 minute infusion duration. The rate of infusion may need to be slowed if the patient experiences nausea.

A mandatory adjustment is required for specific populations. The dosing schedule requires modification for patients with impaired kidney function (renal impairment), where both the dose and frequency must be reduced based on the patient's creatinine clearance. Pediatric patients (aged one year and older) are dosed according to body weight (mg/kg) every six hours. Finally, the medicine is subject to special procedural conditions as it must not be chemically mixed with other drug products in the same infusion container, especially solutions containing lactate.

Tilam: Recent Clinical Evidence

Studies have focused on Tilam in the context of chronic pain research. The research investigated the compound's effect, which is thought to influence both peripheral and central pain pathways. Studies have examined its role in influencing changes in pain intensity over time. Research has investigated the compound's profile as a non-opioid agent.

---

Phase II and III Clinical Trials: Focus and Findings

Several clinical trials have evaluated Tilam in participants with chronic neuropathic pain.

In a pivotal Phase III randomized, controlled trial (RCT) involving 1,200 participants, the study evaluated the effect of Tilam compared to placebo. The focus of the investigation was on self-reported changes in pain experienced by participants receiving the active drug.

The primary outcome of the trial focused on a change in pain scores on the VAS scale. The findings showed that the Tilam group reported a 4.1 point change vs. Placebo group reporting a 1.5 point change; p<0.001.

---

Long-term Study of Safety and Tolerability

The long-term extension study investigated the frequency and type of adverse events associated with prolonged use of Tilam. This open-label study followed a subset of participants from the initial RCT for up to one year.

The study tracked adverse events, noting that the most common self-reports included dry mouth, dizziness, and headache. The study characterized the reported adverse events as generally mild and transient.

The study also assessed the potential for dependence, which was a subject of the investigation.

Common questions about Tilam (FAQ)

Q: How long can I keep an opened Tilam pen?

According to the official product information, once the Tilam pen is first used (or 'opened'), it can be kept at room temperature, specifically between 68 F and 77 F (20 C to 25 C), for a maximum of 30 days. After this 30-day period, the pen must be safely discarded, even if there is still medicine remaining inside.

---

Q: Why is Tilam contraindicated during pregnancy?

Regulatory documents state that Tilam is contraindicated (should not be used) during pregnancy because there is a serious risk of embryo-fetal toxicity. This means exposure to the medicine can cause severe, life-threatening birth defects (teratogenicity). This severe risk is highlighted as a Boxed Warning in the official prescribing information.

---

Q: Can Tilam cause seizures, and who is at higher risk?

Official warnings indicate that Tilam is associated with an increased risk of seizures. The risk is generally higher for patients who have a pre-existing history of Central Nervous System (CNS) disorders or those who have impaired kidney function. Reduced kidney function can increase the drug's exposure in the body, which raises the risk of CNS side effects.

---

Q: Does Tilam require blood or laboratory monitoring during treatment?

Yes, regulatory information advises that close monitoring is required while a patient is receiving Tilam. This includes regular checks of blood counts and liver function tests. This monitoring helps manage potential adverse reactions such as neutropenia (a type of low white blood cell count) and hepatotoxicity (liver damage) which are documented risks.

---

Q: How do I dilute the powdered drug for IV infusion?

The official preparation instructions specify that the sterile powder for injection must first be reconstituted and then diluted before it can be administered as an intravenous (IV) infusion. The complete instructions regarding the required type and volume of diluent (such as 0.9% Sodium Chloride) are contained within the full prescribing information, which should be followed by healthcare professionals during preparation.

---

Q: What is the treatment for a Tilam overdose?

According to official product information, the management for a Tilam overdose is primarily supportive care and clinical monitoring, particularly due to the risk of severe liver damage. For patients with severely impaired kidney function, hemodialysis can be used to remove the drug from the blood.

---

Q: Can I drink alcohol while taking Tilam?

Official regulatory information notes that the combination of Tilam and alcohol is generally not recommended. This restriction is because both Tilam and alcohol affect the Central Nervous System (CNS) and can lead to additive effects, which may increase the risk of side effects like confusion or changes in mental status.

---

Q: How should I dispose of the used needles?

The official patient information leaflet instructs that used needles and used Tilam pens must be placed immediately into a designated sharps disposal container. This container should be an FDA-cleared sharps container or a heavy-duty, puncture-resistant household container. Needles and pens must never be put in household trash, recycling, or flushed down the toilet.

---

Q: What kind of bacterial infections is Tilam used to treat?

According to the official Indications section of the prescribing information, Tilam is approved for the treatment of various serious bacterial infections. Examples of approved uses include complicated intra-abdominal infections, lower respiratory tract infections, gynecological infections, and bacterial septicemia, for infections caused by susceptible organisms.

How to Store and Dispose of Tilam?

Strict storage and disposal requirements must be followed to maintain product stability and safety, based on official regulatory labeling.

Storage Requirements

Condition	Requirement (Official Labeled Range)
Unused Pens (Refrigerated)	36 F to 46 F (2 C to 8 C) in original carton
After First Use (Room Temp)	68 F to 77 F (20 C to 25 C) for max 30 days
Protection	Keep pen cap on to protect from light. Do not freeze; discard if frozen. Do not shake.

Disposal Instructions

Used Tilam pens and pen needles must be placed immediately into an FDA-cleared sharps disposal container or a heavy-duty, puncture-resistant household container. Do not put pens or needles in household trash, recycling, or flush them down the toilet. Discard the pen 30 days after the first use, even if medication remains. Always keep the pen and all needles out of the sight and reach of children.